Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanshen Laifu granule is a Traditional Chinese Medicine (TCM) formulation developed by The Affiliated Hospital of Hunan Academy of Chinese Medicine. It is specifically indicated for the recovery period of COVID-19 infection, targeting post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. The formulation is designed to alleviate persistent symptoms such as fatigue, shortness of breath, and physical weakness. It is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled clinical trial (ChiCTR2400080348) to establish its efficacy and safety profile in patients recovering from COVID-19.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanshen Laifu granule.